NO20053537L - Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi. - Google Patents

Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi.

Info

Publication number
NO20053537L
NO20053537L NO20053537A NO20053537A NO20053537L NO 20053537 L NO20053537 L NO 20053537L NO 20053537 A NO20053537 A NO 20053537A NO 20053537 A NO20053537 A NO 20053537A NO 20053537 L NO20053537 L NO 20053537L
Authority
NO
Norway
Prior art keywords
insulin
control
preparations
prevention
methods
Prior art date
Application number
NO20053537A
Other languages
English (en)
Inventor
Daniel Trevor Green
Robert R Henry
Original Assignee
Diobex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diobex Inc filed Critical Diobex Inc
Publication of NO20053537L publication Critical patent/NO20053537L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Det er beskrevet farmasøytiske preparater omfattende både insulin og glucagon som kan administreres for å kontrollere og behandle diabetes samtidig som faren for insulinindusert hypoglykemi reduseres eller elimineres.
NO20053537A 2002-12-27 2005-07-19 Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi. NO20053537L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43673502P 2002-12-27 2002-12-27
US45497203P 2003-03-14 2003-03-14
US47034603P 2003-05-13 2003-05-13
PCT/US2003/041103 WO2004060387A1 (en) 2002-12-27 2003-12-23 Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Publications (1)

Publication Number Publication Date
NO20053537L true NO20053537L (no) 2005-08-26

Family

ID=32719167

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053537A NO20053537L (no) 2002-12-27 2005-07-19 Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi.

Country Status (11)

Country Link
US (2) US7314859B2 (no)
EP (1) EP1578437A4 (no)
JP (1) JP2006514990A (no)
KR (1) KR20050086948A (no)
CN (1) CN1732012A (no)
AU (1) AU2003303634B2 (no)
CA (1) CA2509755A1 (no)
MX (1) MXPA05006994A (no)
NO (1) NO20053537L (no)
NZ (1) NZ541365A (no)
WO (1) WO2004060387A1 (no)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1808438E (pt) 1999-06-29 2015-01-14 Mannkind Corp Purificação e estabilização de péptidos e proteínas em agentes farmacêuticos
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ATE385193T1 (de) 2002-03-20 2008-02-15 Mannkind Corp Inhalationsgerät
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US7314859B2 (en) 2002-12-27 2008-01-01 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
WO2005056087A1 (en) * 2003-12-05 2005-06-23 Cardinal Health 303, Inc. Patient-controlled analgesia with patient monitoring system
JP2008505087A (ja) * 2004-06-29 2008-02-21 ディオベックス， インコーポレイテッド インスリン誘発性低血糖の予防および制御のための組成物ならびに方法
CA2575692C (en) 2004-08-20 2014-10-14 Mannkind Corporation Catalysis of diketopiperazine synthesis
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
WO2007011958A2 (en) * 2005-07-15 2007-01-25 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
DK1937219T3 (en) 2005-09-14 2016-02-15 Mannkind Corp A method for drug formulation based on increasing the affinity of the crystalline surfaces of the microparticle of active principles
CA2913805A1 (en) * 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
IN2015DN00888A (no) 2006-02-22 2015-07-10 Mannkind Corp
KR20130123470A (ko) * 2007-10-24 2013-11-12 맨카인드 코포레이션 활성제의 전달
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
ES2719305T3 (es) * 2008-04-04 2019-07-09 Hygieia Inc Sistema para optimizar un régimen de dosificación de insulina para un paciente
US9220456B2 (en) 2008-04-04 2015-12-29 Hygieia, Inc. Systems, methods and devices for achieving glycemic balance
US10624577B2 (en) 2008-04-04 2020-04-21 Hygieia, Inc. Systems, devices, and methods for alleviating glucotoxicity and restoring pancreatic beta-cell function in advanced diabetes mellitus
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
KR101933816B1 (ko) 2008-06-13 2019-03-29 맨카인드 코포레이션 건조 분말 흡입기 및 약물 투여 시스템
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI532497B (zh) * 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
AU2009293019A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
US8992464B2 (en) 2008-11-11 2015-03-31 Hygieia, Inc. Apparatus and system for diabetes management
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9375529B2 (en) 2009-09-02 2016-06-28 Becton, Dickinson And Company Extended use medical device
US8573027B2 (en) 2009-02-27 2013-11-05 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
WO2011014704A2 (en) 2009-07-30 2011-02-03 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
EP2335755A1 (en) 2009-12-17 2011-06-22 Sanofi-Aventis Deutschland GmbH Device and method for delivery of two or more drug agents
WO2011117417A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
JP6054861B2 (ja) 2010-03-26 2016-12-27 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
BR112013024076A2 (pt) 2011-03-28 2016-12-06 Novo Nordisk As análogos de glucagon
JP6133270B2 (ja) 2011-04-01 2017-05-24 マンカインド コーポレイション 薬剤カートリッジのためのブリスター包装
RU2483749C2 (ru) * 2011-04-15 2013-06-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде биопленки
RU2483748C2 (ru) * 2011-04-15 2013-06-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде пластыря
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
TWI596110B (zh) 2011-09-23 2017-08-21 諾佛 儂迪克股份有限公司 新穎升糖素類似物
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
ES2624294T3 (es) 2012-07-12 2017-07-13 Mannkind Corporation Sistemas de suministro de fármacos en polvo seco
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
US10201656B2 (en) 2013-03-13 2019-02-12 Tandem Diabetes Care, Inc. Simplified insulin pump for type II diabetics
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9492608B2 (en) 2013-03-15 2016-11-15 Tandem Diabetes Care, Inc. Method and device utilizing insulin delivery protocols
EP2970149B1 (en) 2013-03-15 2019-08-21 MannKind Corporation Microcrystalline diketopiperazine compositions and methods
AU2014255608B2 (en) 2013-04-18 2018-01-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
BR112016000937A8 (pt) 2013-07-18 2021-06-22 Mannkind Corp formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
AU2014339922B2 (en) * 2013-10-24 2019-05-23 Trustees Of Boston University Infusion system for preventing mischanneling of multiple medicaments
EP3086828B1 (en) 2013-12-26 2023-08-09 Tandem Diabetes Care, Inc. Integration of infusion pump with remote electronic device
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
CN106029088A (zh) 2014-02-18 2016-10-12 诺和诺德股份有限公司 稳定的胰高血糖素类似物以及用于治疗低血糖的用途
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
WO2016069475A1 (en) 2014-10-27 2016-05-06 Aseko, Inc. Subcutaneous outpatient management
JP6858751B2 (ja) 2015-08-20 2021-04-14 アセコー インコーポレイテッド 糖尿病管理療法アドバイザ
JP7001584B2 (ja) * 2015-09-04 2022-01-19 ラティチュード ファーマシューティカルズ インコーポレイテッド 安定化されたグルカゴン溶液
US11013873B2 (en) * 2017-01-06 2021-05-25 HealthPartners Institite Methods for treating patients with impaired awareness of hypoglycemia
CN110446496A (zh) * 2017-02-03 2019-11-12 范德比尔特大学 用于治疗糖尿病的系统、组合物和方法
WO2020130751A1 (ko) * 2018-12-21 2020-06-25 한미약품 주식회사 인슐린 및 글루카곤을 포함하는 약학 조성물
AU2022263996A1 (en) 2021-04-27 2023-11-02 Aardvark Therapeutics, Inc. Combination of bitter receptor agonist and gut-signaling compound
GB202109087D0 (en) 2021-06-24 2021-08-11 Norwegian Univ Sci & Tech Ntnu Therapeutic methods and devices

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB748857A (en) 1952-12-16 1956-05-09 Nyegaard & Co As Process for the making of adrenocorticotrophin (acth) preparations having a prolonged action from acth with high specific activity
GB766994A (en) 1953-11-13 1957-01-30 Novo Terapeutisk Labortorium A Improved process in crystallization of insulin
GB766995A (en) 1953-11-14 1957-01-30 Novo Terapeutisk Labor As Improvements in or relating to the production of insulin crystals
US2902408A (en) * 1957-09-12 1959-09-01 Organon Suspensions of drugs destined for injection and process for the preparation thereof
GB831907A (en) 1957-09-12 1960-04-06 Organon Labor Ltd Suspensions of drugs destined for injection and process for the preparation thereof
GB844434A (en) 1958-01-31 1960-08-10 Organon Nv Insulin preparations and process for preparing same
US3897551A (en) * 1971-04-05 1975-07-29 Lilly Co Eli Iodoglucagons and process for prolonging the biological activity of glucagon
US4003379A (en) * 1974-04-23 1977-01-18 Ellinwood Jr Everett H Apparatus and method for implanted self-powered medication dispensing
US4498843A (en) * 1982-08-02 1985-02-12 Schneider Philip H Insulin infusion pump
IT1170375B (it) * 1983-04-19 1987-06-03 Giuseppe Bombardieri Apparecchio che infonde insulina o glucosio nel soggetto diabetico sulla base di determinazioni di concentrazioni di glucosio ottenute senza bisogno di prelievi del sangue del paziente
CA1196863A (en) * 1983-06-08 1985-11-19 Mattheus F.A. Goosen Slow release injectable insulin composition
US4538616A (en) * 1983-07-25 1985-09-03 Robert Rogoff Blood sugar level sensing and monitoring transducer
DK27885A (da) * 1985-01-22 1986-07-23 Novo Industri As Fremstilling af peptider
AT391998B (de) * 1987-02-02 1990-12-27 Falko Dr Skrabal Vorrichtung zur bestimmung der konzentration zumindest einer medizinischen substanz in lebenden organismen
US4879273A (en) 1987-05-22 1989-11-07 The Rockefeller University Glucagon homologs and therapeutic use thereof
NL8701644A (nl) 1987-07-13 1989-02-01 Cordis Europ Inrichting voor dosering in het lichaam van een vloeibaar materiaal.
US4839174A (en) * 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US4943435A (en) * 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US5190041A (en) * 1989-08-11 1993-03-02 Palti Yoram Prof System for monitoring and controlling blood glucose
US5101814A (en) * 1989-08-11 1992-04-07 Palti Yoram Prof System for monitoring and controlling blood glucose
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5527771A (en) * 1991-01-10 1996-06-18 Amylin Pharmaceuticals, Inc. Methods and Compositions for treatment of diabetes mellitus, hypoglycemia & other conditions
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5814600A (en) * 1991-05-24 1998-09-29 Amylin Pharmaceuticals Inc. Method and composition for treatment of insulin requiring mammals
DE69221725T2 (de) * 1991-05-24 1997-12-18 Amylin Pharmaceuticals, Inc., San Diego, Calif. Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
CN1134110A (zh) * 1993-09-07 1996-10-23 安米林药品公司 调节胃肠动力的方法
US5512468A (en) * 1993-11-12 1996-04-30 Stratagene Process of producing highly transformable bacterial cells and cells produced thereby
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
NL9401886A (nl) 1994-05-27 1996-01-02 Dsm Nv Samenstelling bestaande uit een dendrimeer en een in het dendrimeer opgesloten actieve stof, een werkwijze voor de bereiding van een dergelijke samenstelling en een werkwijze voor het vrijgeven van de actieve stof.
US5474552A (en) * 1994-06-27 1995-12-12 Cb-Carmel Biotechnology Ltd. Implantable drug delivery pump
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
WO1996028475A1 (fr) 1995-03-10 1996-09-19 Nakamura, Toshikazu Facteur de croissance des hepatocytes modifie a l'aide de polyethylene glycol
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
IL114673A (en) 1995-07-19 2000-12-06 Hadasit Med Res Service Pharmaceutical compositions containing protein for oral administration
US5849322A (en) * 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
US5741211A (en) * 1995-10-26 1998-04-21 Medtronic, Inc. System and method for continuous monitoring of diabetes-related blood constituents
AU1520097A (en) 1995-12-27 1997-07-28 Genentech Inc. Ob protein derivatives having prolonged half-life
AU2549297A (en) * 1996-03-28 1997-10-17 Board Of Trustees Of The University Of Illinois, The Materials and methods for making improved echogenic liposome compositions
IL118003A0 (en) * 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
EP1826216A1 (en) 1996-08-30 2007-08-29 Novo Nordisk A/S Glp-1 derivatives
CN1168495C (zh) 1997-01-15 2004-09-29 凤凰药理学公司 被修饰的肿瘤坏死因子
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
US5869062A (en) * 1997-05-27 1999-02-09 Oliver; Benjamin Skin treatment composition
US5919216A (en) * 1997-06-16 1999-07-06 Medtronic, Inc. System and method for enhancement of glucose production by stimulation of pancreatic beta cells
US6093167A (en) * 1997-06-16 2000-07-25 Medtronic, Inc. System for pancreatic stimulation and glucose measurement
US6437092B1 (en) * 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
AU1384199A (en) * 1997-11-07 1999-05-31 Chiron Corporation Method for producing igf-1 sustained-release formulations
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
US6107489A (en) * 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
KR19990085365A (ko) * 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
RU2205188C2 (ru) * 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
CN1329502A (zh) * 1998-12-04 2002-01-02 普罗瓦利斯英国有限公司 含有胰岛素的药物组合物
US20020114829A1 (en) * 1998-12-18 2002-08-22 Hayat Onyuksel Materials and methods for making improved liposome compositions
US6360888B1 (en) * 1999-02-25 2002-03-26 Minimed Inc. Glucose sensor package system
US6261280B1 (en) * 1999-03-22 2001-07-17 Medtronic, Inc Method of obtaining a measure of blood glucose
ATE251466T1 (de) * 1999-04-08 2003-10-15 Genentech Inc Zusammensetzung auf basis gegensätzlich geladener polypeptide
US6319510B1 (en) * 1999-04-20 2001-11-20 Alayne Yates Gum pad for delivery of medication to mucosal tissues
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
ES2209885T3 (es) * 1999-05-17 2004-07-01 Conjuchem, Inc. Peptidos insulinotropicos de larga duracion.
US6461331B1 (en) * 1999-05-21 2002-10-08 Minimed Inc. Device and method for infusion of small molecule insulin mimetic materials
US20020026141A1 (en) * 1999-11-04 2002-02-28 Medtronic, Inc. System for pancreatic stimulation and glucose measurement
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
WO2001064149A1 (en) * 2000-02-29 2001-09-07 Jie Zhang Improved transdermal drug patch
US6572542B1 (en) * 2000-03-03 2003-06-03 Medtronic, Inc. System and method for monitoring and controlling the glycemic state of a patient
US6548049B1 (en) 2000-05-01 2003-04-15 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6565833B1 (en) 2000-05-01 2003-05-20 Aeropharm Technology Incorporated Medicinal aerosol formulation
DK1320387T3 (da) 2000-09-13 2012-07-16 Glaxosmithkline Llc Farmaceutiske sammensætninger til vedvarende afgivelse af peptider
JP5170931B2 (ja) 2000-10-16 2013-03-27 中外製薬株式会社 Ｐｅｇ修飾エリスロポエチン
WO2002043566A2 (en) 2000-11-28 2002-06-06 Baum Martin G Devices and methods for treating low blood sugar levels
KR20080085082A (ko) 2000-12-07 2008-09-22 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 융합 단백질
US6656590B2 (en) * 2001-01-10 2003-12-02 Cabot Corporation Coated barium titanate-based particles and process
WO2002056763A2 (en) * 2001-01-22 2002-07-25 Integrated Sensing Systems, Inc. Mems capacitive sensor for physiologic parameter measurement
CA2502068A1 (en) * 2002-11-18 2004-06-03 Pfizer Products Inc. Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides
US7314859B2 (en) 2002-12-27 2008-01-01 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
JP5037496B2 (ja) 2005-05-13 2012-09-26 トラスティーズ オブ ボストン ユニバーシティ １型糖尿病用の完全自動制御システム

Also Published As

Publication number Publication date
US20080096801A1 (en) 2008-04-24
JP2006514990A (ja) 2006-05-18
EP1578437A4 (en) 2006-08-09
AU2003303634A1 (en) 2004-07-29
NZ541365A (en) 2009-09-25
US7314859B2 (en) 2008-01-01
US7642232B2 (en) 2010-01-05
MXPA05006994A (es) 2005-10-18
CA2509755A1 (en) 2004-07-22
CN1732012A (zh) 2006-02-08
EP1578437A1 (en) 2005-09-28
US20060160722A1 (en) 2006-07-20
WO2004060387A1 (en) 2004-07-22
AU2003303634B2 (en) 2009-10-01
KR20050086948A (ko) 2005-08-30

Similar Documents

Publication Publication Date Title
NO20053537L (no) Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi.
Heise et al. Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: a randomized, double‐blind, crossover trial
Heise et al. Faster‐acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart
Ratner et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre‐planned meta‐analysis of phase 3 trials
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
NO20003051L (no) Metode for administrering av AspB28-humant insulin
MXPA05003346A (es) Control glicemico mejorado para prediabetes y/o diabetes tipo ii utilizando acido docosahexaenoico.
BRPI0406499A (pt) Insulina de longa atuação para redução da morbidez e mortalidade cardiovascular em pacientes pré-diabéticos e pacientes com diabetes tipo 2
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
HUP0300325A2 (hu) A cukorbetegséggel járó szövődmény és neuropátia kezelésére szolgáló gyógyszerkészítmények és ezek alkalmazásai és előállításuk
HUP0401998A2 (hu) PDE9 inhibitorok alkalmazása olyan gyógyszer előállítására, amellyel inzulin-rezisztencia szindróma és 2-es típusú diabétesz kezelhető
HUP0300642A2 (hu) Antidiabetikus készítmény és alkalmazása
BRPI0414146A (pt) aparelho para o controle da glicose no sangue
NO20053041L (no) Behandling av diabetes.
UA88440C2 (ru) ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β
HUP0002373A2 (hu) Glükagon antagonisták/inverz agonisták és ezeket tartalmazó gyógyászati készítmények
BR0207700A (pt) Método para tratar a diabete melito em um paciente em necessidade de tal tratamento, e, usos de um derivado de polipeptìdeo de insulina, e de um conjugado de polipeptìdeo de insulina-oligÈmero
BRPI0410972C1 (pt) método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia
WO2004050115A3 (en) Combination treatment using exendin-4 and thiazolidinediones
NO20070174L (no) Preparater og fremgangsmater for forebyggelse og kontroll av insulindindusert hypoglykemi
NO20061417L (no) Syreinneholdende oxaliplatinformuleringer
Einhorn et al. Patients achieving good glycemic control (HbA1c< 7%) experience a lower rate of hypoglycemia with insulin degludec than with insulin glargine: a meta-analysis of phase 3a trials
WO2005117937A3 (en) Alpha-1- acid glycoprotein for the treatment of diabetes
Maideen Pharmacologically relevant drug interactions of glucagon-like peptide-1 receptor agonists
DE60222383D1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application